U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases announces the availability of funding for implementation of the Host-Directed Tuberculosis (TB) Therapy: New Approaches (UH2/UH3) Grant. The purpose of this grant is to support pre-clinical evaluation, planning, and conducting proof-of-concept clinical studies for mycobacterium TB treatment that will be applicable in the context of HIV co-infection using host-directed agents already approved for clinical use or in late-stage clinical trials for other conditions. Contractors should refer to Section VII, Agency Contacts, in the . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

RFP | November 13, 2014

Federal Government Announces Host-Directed TB Therapy: New Approaches (UH2/UH3) Grant Funding

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member